A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis

The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to placebo, and to establish that the therapeutic is safe and generally well tolerated by patients.

Inclusion Criteria: * Symptomatic blepharitis * At least 18 years of age * Eyelid collarette score of at least 2 * Demodex mite density of at least 1.5 mites per lash or higher * Willing and able to follow all instructions and attend all study visit * Able to avoid prohibited medication for the duration of the study * Patients can willingly provide consent on the informed consent form Exclusion Criteria: * Women with confirmed pregnancies * Utilizing any medical or surgical therapy for acute or subacute conditions of the eye * History of allergic reaction to spinosad or any formulation component * Patients using eyelid hygiene or other treatment(s) for blepharitis within 14 days of screening * History of ocular surgery within the past 3 months * Presence of other ocular diseases that may affect study outcomes * Use of investigational drug, chronic glaucoma medications, or steroids * Uncontrolled systemic disease * Acute or chronic illness that would confound study results